158 related articles for article (PubMed ID: 17913550)
1. Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Altundag K; Dede D; Harputluoglu H; Gullu I
Joint Bone Spine; 2007 Dec; 74(6):662-3. PubMed ID: 17913550
[No Abstract] [Full Text] [Related]
2. Aromatase inhibitors and arthralgia.
Donnellan PP; Douglas SL; Cameron DA; Leonard RC
J Clin Oncol; 2001 May; 19(10):2767. PubMed ID: 11352973
[No Abstract] [Full Text] [Related]
3. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
4. [Aromatase inhibitors and arthralgia].
Nagykálnai T; Landherr L; Mészáros E
Magy Onkol; 2011 Mar; 55(1):32-9. PubMed ID: 21617789
[TBL] [Abstract][Full Text] [Related]
5. Getting a grip on aromatase inhibitor-associated arthralgias.
Hershman DL
J Clin Oncol; 2008 Jul; 26(19):3120-1. PubMed ID: 18474872
[No Abstract] [Full Text] [Related]
6. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Sestak I; Sapunar F; Cuzick J
J Clin Oncol; 2009 Oct; 27(30):4961-5. PubMed ID: 19752338
[TBL] [Abstract][Full Text] [Related]
7. A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
Chino A; Okamoto H; Hirasaki Y; Ueda K; Ogawa K; Namiki T
J Altern Complement Med; 2011 Nov; 17(11):1075-7. PubMed ID: 22070441
[TBL] [Abstract][Full Text] [Related]
8. COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.
Hadji P; Jackisch C; Bolten W; Blettner M; Hindenburg HJ; Klein P; König K; Kreienberg R; Rief W; Wallwiener D; Zaun S; Harbeck N
Ann Oncol; 2014 Feb; 25(2):372-7. PubMed ID: 24355487
[TBL] [Abstract][Full Text] [Related]
9. Letrozole or tamoxifen in early breast cancer.
Buzdar AU; Baum M; Cuzick J
N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16598051
[No Abstract] [Full Text] [Related]
10. Extended adjuvant therapy for breast cancer--how much is enough?
Prowell TM; Stearns V
J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
[No Abstract] [Full Text] [Related]
11. Anastrozole.
Cuzick J
Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
13. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
14. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
15. Anastrozole-induced hepatotoxicity.
Zapata E; Zubiaurre L; Bujanda L; Piérola A
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1233-4. PubMed ID: 17033446
[TBL] [Abstract][Full Text] [Related]
16. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Doggrell SA
Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790
[TBL] [Abstract][Full Text] [Related]
17. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
19. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
20. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
